ImmunifyMe Healthcare Technologies Pvt. Ltd., Altrade Business Centre, Gurugram, Haryana, India.
Vector Borne Diseases Group, International Centre for Genetic Engineering & Biotechnology, New Delhi, India.
Indian J Med Res. 2021 May;154(5):669-679. doi: 10.4103/ijmr.IJMR_1219_18.
Multiple dengue virus (DENV) serotypes circulating in a geographical area most often lead to simultaneous infection of two or more serotypes in a single individual. The occurrence of such concurrent infections ranges from 2.5 to 30 per cent, reaching as high as 40-50 per cent in certain dengue hyper-endemic areas. Concurrent dengue manifests itself differently than mono-infected patients, and it becomes even more important to understand the effects of co-infecting serotypes in concurrent infections to ascertain the clinical outcomes of the disease progression and transmission. In addition, there have also been reports of concurrent DENV infections in the presence of other arboviral infections. In this review, we provide a comprehensive breakdown of concurrent dengue infections globally. Furthermore, this review also touches upon the clinical presentations during those concurrent infections categorized as mild or severe forms of disease presentation. Another aspect of this review was aimed at providing insight into the concurrent dengue incidences in the presence of other arboviruses.
多种登革热病毒(DENV)血清型在一个地理区域内循环,通常会导致一个人同时感染两种或两种以上的血清型。这种同时感染的发生率在 2.5%至 30%之间,在某些登革热高度流行地区高达 40-50%。同时感染的登革热与单感染患者表现不同,因此更需要了解同时感染的血清型的影响,以确定疾病进展和传播的临床结果。此外,也有报告称在存在其他虫媒病毒感染的情况下同时感染 DENV。在这篇综述中,我们全面介绍了全球范围内的同时感染登革热的情况。此外,这篇综述还涉及到那些同时感染时表现为轻度或重度疾病的临床表现。这篇综述的另一个方面是提供在存在其他虫媒病毒的情况下同时感染登革热的发生率的见解。